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Introduction
Clinical diversity is a common phenomenon in lysosomal 
storage diseases and has led to the introduction of clinical sub-
types. The natural course of Pompe disease is primarily dictated 
by the type of mutations in the acid alpha-glucosidase gene 
(GAA) or rather by the residual enzyme activity of acid alpha-
glucosidase resulting from the combination of the mutated al-
lelic products. Thirty per cent of normal acid-alpha-glucosidase 
activity in skeletal muscle is the critical threshold below which 
lysosomal glycogen storage starts and disease symptoms mani-
fest. Patients with late onset Pompe disease generally have more 
acid-alpha-glucosidase activity in muscle cells and/or fibrob-
lasts than severely affected infants with classic infantile Pompe 
disease. These latter never have more than 2% of normal acid-
alpha-glucosidase activity. The so-called adult form of Pompe 
disease is not an autonomous entity with respect to the classic 
and juvenile ones, but differs from them mainly for the lower 
speed of accumulation of glycogen within the lysosomes which 
explains the late onset of skeletal muscle tissue changes and 
clinical manifestations. 
Epidemiology and first diagnosis
The adult form of Pompe disease has an incidence of one 
on 57.000 newborn per year. It manifests by convention after 
eighteen years of age. Actually if we consider data from the lit-
erature and our own it emerges that the first diagnosis is usually 
made within the third or the fourth decades of life (the mean 
age of the patients at the diagnosis ranges 27-41.4 years, in the 
series of van der Beek (1) and Müller-Felber (2), respectively). 
By careful history collection, however, it is almost always pos-
sible to date many years back the early disease manifestations 
(3 to 10 years on average). This relatively long and variable time 
interval between first symptoms and correct diagnosis is mainly 
related to the slow progression of symptoms which are rela-
tively unspecific at least in the first phases of the disease. This 
frequently leads both the patient and his doctor to underestimate 
the importance of the early symptoms and an incorrect diagno-
sis at this phase of the disease is usually the rule. A further ele-
ment of confusion for many practitioners is that Pompe disease 
is better known as an infantile disease and is ignored, as a rule, 
in conditions which involves adults.
It is interesting, that in his series of patients with adult-
onset Pompe disease Müller-Felber (2) calculated that it passes 
7 years on average between the first medical consultation for 
symptoms related to the disease and the correct diagnosis. This 
time interval decreases to 3 years, on average, in the series of 
Dutch patients of van der Beek (1). This better performance is 
likely due to the widespread awareness of the disease among 
the physicians of the same country of doctor Pompe. These data 
demonstrate how important is to organize educational events to 
improve the knowledge of Pompe disease among medical pro-
fessionals.
Symptoms at onset
The  symptoms  more  frequently  complained  by  patients 
are reported in Table 1. These are represented by slowly pro-
gressing reduction of muscle strength, which mainly involves 
lower limbs. This causes difficulties with running and walking, 
climbing up and down stairs, getting up easily from chairs, and 
rising up from a lying position. Almost all the patients retro-
spectively remember difficulties during physical education or 
athletic games during their childhood. These symptoms are as-
sociated with, or often preceded by, diffuse muscle pain, lumbar 
pain and muscle cramps at the lower limbs. Profound tiredness 
even after moderate exercise as well as frequent downfall are 
reported. In about 13% of the patients the very first symptoms 
are represented by respiratory difficulties, with recurrent pul-
monary infections, dyspnea even after moderate exercise, as 
well as snoring, headache at awakening and daytime sleepiness 
due to sleep-disordered breathing and nightly hypoventilation. 
Gradual body weight loss, due to lack of appetite and difficult 
swallowing, cardiac arrhythmias, hearing loss and moderately 
increased Creatine Kinase (it is often an incidental finding) are 
less frequently reported symptoms which should lead back to 
the disease.
As mentioned above onset symptoms are nonspecific and 
are not likely to suggest Pompe disease, unless the diagnosis 
has already been made in some relatives. In the later case, even 
the most trivial of these symptoms becomes a wake-up call to 
the patient and the physician. Otherwise it is only the progres-
sive  deterioration  of  motor  performance  and/or  respiratory 
conditions to lead the patient to a specialist of neuromuscular 
diseases.
Clinical features
The clinical picture in these patients is that of a proximal 
myopathy (Table 2), the severity of which varies from patient 
to patient being mainly related to the duration of the disease at 
the time of the observation. Pelvic girdle muscles and proximal 
muscles of lower limbs are almost always earlier and more se-
verely affected than those of the shoulder girdle and upper limbs. 
In particular, in this disorder there is a preferential involvement 
of glutei, adductors of the thigh, and paraspinal muscles. This 
Table 1. Symptoms at onset.
Progressive limitation in walking
Diffuse myalgias, muscle cramps
Intolerance to exercise
Frequent falls
Recurrent pulmonary infections
Dyspnea on exertion
Morning headaches
Daytime sleepiness
Weight loss
Difficulty in swallowing
Heart rhythm disturbances
Hearing loss
Elevated CK201
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explains the waddling gait, the lumbar hyperlordosis sometimes 
accompanied with scoliosis, and the Gower’s maneuver, which 
usually occur in these patients. Subsequently, the weakening 
manifests, even if to a lesser extent, at the shoulder girdle mus-
cles. Particularly involved are the fixators of the scapula (lower 
trapezius, rhomboid, and subscapularis), and the neck flexors 
(sternocleidomastoid) and this explains features such as wing-
ing scapula and difficulty of the patient in lifting his head while 
lying in the supine position. The weakness of segmental and ax-
ial muscles is associated with a more or less early weakness of 
the respiratory muscles (diaphragm and intercostals muscles). 
For this reason, it is always advisable in the clinical evaluation 
of these patients to inquire if they complain of related disorders 
such  as  orthopnea,  exertional  dyspnea,  ineffective  coughing, 
which are initial signs of respiratory failure. For this purpose, 
it is useful to invite the patient to count out loud during the ex-
piratory phase, first supine and then sitting. A lower count in 
the supine position is indicative of a reduced vital capacity. The 
finding of a reduced vital capacity is important from the point of 
view of the diagnostic process, and should prompt physicians to 
refer the patient to the pulmonologist for a more thorough clini-
cal and instrumental evaluation. 
The phenotypic spectrum of late-onset forms has, however, 
enriched with other features (3), although rare (Table 3). Apart 
from the involvement of the muscles of mastication and swal-
lowing, cases have been reported with ptosis and a distribution 
of muscle weakness with a scapulo-peroneal pattern. Rhythm 
disturbances  such  as  Wolf-Parkinson-White  syndrome  have 
been reported, as well as aneurysms of the basilar artery, the 
carotid arteries, and the thoracic aorta. The frequent detection of 
such abnormalities should prompt a search for their presence in 
all patients with Pompe disease. The muscle weakness is always 
associated with a gradual muscle wasting and reduced reflexes. 
Cognitive, sensory and cerebellar disorders as well as a cardio-
myopathy have never been observed. 
Differential diagnosis 
The clinical presentation of Pompe disease in the adult, 
which is almost always that of a predominantly proximal my-
opathy with prevailing expression at level of the pelvic girdle, is 
nonspecific, and such to induce to make an alternative diagno-
sis, in the first instance. Some of these alternative diagnosis are 
shown in Table 4. Many of these conditions are easily refuted 
by applying the usual diagnostic protocol for neuromuscular 
diseases. A differential diagnosis may be challenging with some 
forms of autosomal recessive limb-girdle dystrophies, especial-
ly the 2A or calpainopathy and the 2I, as well as with the Danon 
disease, a vacuolar myopathy in which, however, there is always 
a cardiomyopathy. Several diagnostic algorithms have been pro-
posed for the diagnosis of Pompe disease in the adult (4). All 
are modeled in their general lines and in the early stages on the 
protocol that is implemented for each neuromuscular disorder: 
clinical evaluation, measurement of muscle enzymes in serum 
(this must be done in all patients with respiratory disorders not 
related to lung and/or cardiac diseases and in all patients with 
an involvement of the diaphragm!), and EMG/ENG evaluation. 
The detection of suggestive features of Pompe’s disease or of a 
nonspecific myopathy places the indication to a muscle biopsy. 
This last showing a vacuolar myopathy with accumulation of 
glycogen suggests Pompe disease and leads to perform the as-
say acid alpha-glucosidase activity in various tissues (this can 
be done on skeletal muscle, fibroblasts, or blood). Values of 
enzyme activity equal to or less than 30% of normal indicate 
by themselves the diagnosis of Pompe disease, which must be 
finally confirmed by bio-molecular analysis of GAA gene. 
Conclusions 
An early diagnosis offers the patient the opportunity to 
start a therapy that, today, appears able to positively modify the 
natural course of the disease, and address the family to genetic 
counseling. It should not be forgotten that the natural course of 
the disease, although mild and slow, has led invariably to muscle 
impairment of variable degree, prior the enzyme replacement 
therapy  was  available.  Muscle  impairment  significantly  im-
pacts on the quality of life of these patients, causing reduction 
of physical performances, worsening of general health, resiz-
ing of family and social roles related to physical efficiency, and 
social withdrawal. In fact, the progression of the disease leads 
Table 2. Main clinical features.
Skeletal muscles
Weakness of the pelvic girdle muscles (glutei), proximal lower 
extremities (thigh adductors) and paraspinal muscles
•  Waddling gait
•  Gowers’ maneuver
•  Lumbar hyperlordosis with scoliosis
Weakness of the shoulder girdle muscles 
•  Winging scapula
Respiratory muscles 
Weakness of diaphragm and accessory muscles
•  Orthopnea
•  Exertional dyspnea
•  Invalid cough
Table 3. Less frequent clinical features.
Weakness of the muscles of mastication and swallowing
Ptosis
Muscle weakness with scapulo-peroneal pattern of distribution
Rhythm disturbances such as Wolff-Parkinson-White
Basilar and carotid arteries aneurysms, thoracic aorta 
aneurisms
Table 4. Differential diagnosis.
Becker muscular dystrophy
Limb-girdle muscular dystrophies (2A and 2I)
Dystrophy of Emery-Dreifuss 
Spinal Muscular Atrophy type III
Danon disease
Myofibrillar myopathies
Nemaline Myopathy adult form
Metabolic myopathies
Muscle glycogen storage disease (type V, VII)
Polymyositis202
Proceedings of the Meeting Course on Type II Glycogenosis: a network for the treatment of Pompe disease
almost always to loss of autonomous walking and forces the 
patients to use the wheelchair. Lung function becomes increas-
ingly compromised with the duration of the illness and assisted 
ventilation is required by non-invasive methods or by tracheos-
tomy. Dependence on a wheelchair usually starts a decade after 
the diagnosis while that on assisted ventilation may start earlier. 
Respiratory failure is almost always the cause of death in these 
patients. Today it seems possible to stop this tragic sequence of 
events by ERT, but for this purpose it is necessary to diagnose 
the disease at its early stages.
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The  heart  is  part  of  the  clinical  phenotype  of  Glyco-
gen storage disease type II (GDS II; Pompe disease; or acid 
maltase deficiency) since its original description. In 1932, Jo-
hannes Pompe, a Dutch pathologist, described the case of a 
7-month old infant who died suddenly for a severe idiopathic 
hypertrophy of the heart (1). Although other cases of massive 
hypertrophy of the heart have previously been described, Dr. 
Pompe first demonstrated that not only the heart was involved, 
but also other organs showed a vacuolar storage of glycogen 
(“cardiomegalia glycogenica”) (1). From a cardiologist’s point 
of view, Pompe disease is one of the leading cause of familial 
(idiopathic) hypertrophic cardiomyopathy in neonatal and pae-
diatric age (2). GSD II is broadly divided into two onset forms 
based on the age symptoms occur. 
Infantile onset (“Classic” Form)
In the classic infantile form (Pompe disease), cardiomy-
opathy and conduction disorders, along with muscular hypoto-
nia (“floppy baby”), macroglossia, and organomegalia, are the 
cardinal features.
Cardiomyopathy  is  generally  of  the  hypertrophic  type, 
demonstrating a severe thickening of the septum (“asymmetric” 
hypertrophy), or frequently of both the septum and free walls of 
the left and right heart (“concentric” hypertrophy). When the sep-
tal hypertrophy is very pronounced, a left outflow tract obstruc-
tion (favoured by a systolic anterior motion of the anterior mitral 
leaflet) may be present to worsen the disease (about 30% of the 
cases). Both diastolic and systolic dysfunction can be observed. 
Levine JC et al. showed a rapid regression of left ventricular 
hypertrophy in response to enzyme replacement therapy (ERT) 
in most of the patients, and systolic ventricular function was pre-
served despite rapid changes in ventricular mass and size (3). 
Glycogen  storage  involves  not  only  cardiac  myocytes, 
but also the special cells of the conduction system (particu-
larly,  the A-V  node  and  the  His-bundle  cells),  representing 
the hystological background of classical electrocardiographic 
abnormalities in Pompe disease: pre-excitation patterns (short 
PR, delta waves), atrio-ventricular blocks and bundle branch 
abnormalities. The  pathogenesis  of  ventricular  pre-excitation 
(Wolf Parkinson White syndrome, WPW, when symptomatic) 
is unknown, though is clear that the pattern does not reflect the 
presence of an accessory pathway (as in the classic WPW) (4). 
The suggested hypothesis are: a) a “direct insulating effect” of 
the glycogen on the conduction system; b) an “indirect insulat-
ing effect” of the glycogen on the conduction system, by the 
anatomic interruption of the annulus fibrosus (which acts as an 
“electric insulate” between the atria and the ventricles (4). 
Differential diagnosis
A metabolic or mitochondrial cardiomyopathy may mimic 
the presentation of GDSII cardiomyopathy (5). The presence of 
encephalomyopathy, metabolic acidosis (with or without hy-
poglycemia), the increase of lactate and lactate/piruvate ratio 
(normal: < 15:1; abnormal: 25:1) may suggest a mitochondrial 
cardiomyopathy. Hypoglycemia, with or without variation of 
plasma ketones, insulin, free fatty acids or carnitine may repre-
sent an hallmark of metabolic cardiomyopathies (i.e. beta oxi-
dation deficits). 
Infantile onset (“Non Classic” Form)
Compared to the classic form, the onset of the “non classic 
form” of Pompe disease is generally after the first year of age, 
with a less severe picture, including muscle weakness, cardio-
myopathy, and sometimes macroglossia and organomegalia. 
Conduction  abnormalities  and  ECG  signs  of  ventricular 
hypertrophy are generally part of the disease spectrum. Echocar-
diographic appearance of cardiac hypertrophy is generally less 
severe and progressive, lacking the left ventricular obstruction 
and the systolic dysfunction that significantly worsen the classic 
phenotype. However, the clinical presentation may be extremely 
various, as demonstrated by Suzuki et al. (6), which reported on 
a male who developed cardiomyopathy at 12 years of age and 
died of heart failure at age 15 years without any clinical and/or 
histological sign of skeletal myopathy. 
Differential diagnosis
On the cardiology point of view, the differential diagnosis is 
with overlapping phenotypes, including syndromic, mitochondri-
al or metabolic cardiomyopathies (5). Ventricular pre-excitation 
on the ECG and the presence of idiopathic left ventricular hyper-
trophy in children are common feature of storage diseases (AMP-
kinase  disease,  Danon  disease),  and  mitochondrial  disorders 
(MELAS, MERFF). Particularly, Danon disease is an X-linked 
glycogen storage disorder due to the absence of the LAMP-2, lys-
osome-associated membrane protein 2 (evidenced by Immuno-